Follow on Google News News By Tag * Teva * Pharmaceutical * Generic * Litigation * Patent * Lawsuit * Settlement * Files * Victory * Settle * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | "Teva Pharmaceutical Industries Generics Company Intelligence Report" PublishedFast Market Research recommends "Teva Pharmaceutical Industries Generics Company Intelligence Report" from Espicom Business Intelligence, now available
In July 2005, Teva announced a merger with IVAX, one of the USA's leading generic companies. The acquisition was completed in January 2006, in a deal worth some US$7.4 billion. The deal strengthened Teva's position in the USA and Latin America. In 2008, Teva announced it was acquiring the US generic firm, Bentley Pharmaceuticals, in a deal worth some US$360 million. Although based in the US, Bentley's main business was in Spain, with additional operations in other parts of Europe. In July 2008, Teva Pharmaceutical Industries announced plans to acquire Barr in a deal worth some US$7.46 billion. The deal completed in December 2008, creating a company that operates in over 60 countries and employs some 37,000 people. The acquisition drove Teva's North America revenues increase in 2009. While the bulk of Teva's revenues are derived from generics, the company has one major innovative product, Copaxone. This is a treatment for multiple sclerosis. Sales of Copaxone broke the US$1 billion mark in 2005, and were worth US$2.83 billion in 2009. A second innovative product, Azilect (rasagiline, Parkinson's disease), was launched in 2006. Teva is also involved in research in other areas such as drug delivery and biosimilars. In February 2010, the FDA accepted for filing Teva's Biologics Licence Application for XM02, the firm's G-CSF product. Teva submitted its BLA in November 2009, underscoring the firm's scepticism that Congress would be able to create a regulatory pathway for biosimilars. In March 2010, Teva announced that it was to acquire ratiopharm for an enterprise value of 3.625 billion euros (US$4.9 billion). The deal will position Teva as the leading generics player in Europe, and cement its position as the largest generics firm in the world. The acquisition completed on 10th August 2010. For more information or to purchase this report, go to: - http://www.fastmr.com/ Partial Table of Contents: Executive Summary Introduction Strategic review Teva outlines respiratory business growth strategy Products Teva Pharmaceutical Industries: main pharmaceutical manufacturing facilities Generic products North America Europe International Branded products Peptimmune files glatiramer Citizen Petition Biopharmaceuticals and biosimilars Teva updates status of G-CSF BLA Teva plans further study with rituximab biosimilar Teva ANDA Approvals January 2002 - September 2010 Barr Laboratories ANDA Approvals, January 2008 - September 2010 Pliva, Pliva Hrvatska and Pliva Lachema ANDA Approvals, January 2002 - September 2010 Recent product approvals Lamivudine / zidovudine (EU) Docetaxel (EU) Lansoprazole (US) Dorzolamide / timolol ophthalmic solution (UK) Venlafaxine (US) Clopidogrel (EU) Anastrozole (US) Ibandronic acid (EU) Valacyclovir (US) Adapalene (US) Teva launches new generic oral contraceptive (US) Atorvastatin (Canada) Cinacalcet (US, tentative) Tamsulosin (US) Losartan (US) Temozolomide (UK) Argatroban injection (US, tentative) Losartan (UK) CHMP accepts safety of clopidogrel generics CHMP update includes selected drugs for musculoskeletal and genetic diseases Lercanidipine (UK) Dorzolamide eye drops (UK) Letrozole (US, tentative) Levodopa / benserazide (UK) Atomoxetine (US, tentative) CHMP adopts positive opinion on Temodal generics Filgrastim (UK) Fexofenadine (US) Nateglinide Triamcinolone Levonorgestrel Bicalutamide Ethinyloestradiol, norgestimate Financial results Latest Quarterly Results, Q310 Teva Pharmaceutical Industries: quarterly results, in US$ millions Latest Fiscal Year Results, 2009 Teva Pharmaceutical Industries: fiscal year results, in US$ millions Sales North America Europe International Teva Pharmaceutical Industries: sales by geographical areas, in US$ millions Global Branded Products Biogenerics and biopharmaceuticals Teva Pharmaceutical Industries: sales by product line, in US$ millions Major developments Teva opens a new pharmaceutical packaging plant in Hungary Teva invests in Ontario Mergers, acquisitions and agreements Teva to acquire Theramex to expand global women's health business Teva acquires ratiopharm Teva invests additional US$11.9 million in Andromeda Teva-KOWA Pharma to acquire majority interest in Taisho Pharmaceutical Industries Codexis expands collaboration with Teva Abbott and Fournier enter fenofibrate licence agreement with Teva Vical grants Teva sales and marketing rights for Allovectin-7 in Israel Antares receives payment from Teva for commercial development of Vibex product Litigation Eli Lilly gains pemetrexed patent victory Merck claims temozolomide patent lawsuit victory Watson confirms rasagiline patent challenge Nycomed and Pfizer see pantoprazole litigation success Forest / Merz settle memantine litigation Astellas and Teva reach solifenacin patent litigation settlement Rosuvastatin patent upheld in court Teva sued by Bayer over oral contraceptive product Barr withdraws thalidomide ANDA; Celgene dismisses lawsuit Full Table of Contents is available at: -- http://www.fastmr.com/ About Espicom Business Intelligence Espicom Business Intelligence is a highly-regarded and established provider of business intelligence services. Founded in 1982 as MDIS Publications Ltd, the company changed its name to Espicom in 1992. Initially a publisher in a wide range of industries such as power generation and telecommunications, they now focus on the global pharmaceutical and medical device sectors. View more research from Espicom Business Intelligence at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number